Regeneron (REGN) Gets a Buy from Piper Sandler

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,016.00. The company’s shares closed last Friday at $896.82.

According to TipRanks, Raymond is a 4-star analyst with an average return of 3.6% and a 48.80% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $1,041.47, implying a 16.13% upside from current levels. In a report released on April 17, Jefferies also assigned a Buy rating to the stock with a $1,060.00 price target.

The company has a one-year high of $998.33 and a one-year low of $684.81. Currently, Regeneron has an average volume of 469.2K.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Most recently, in February 2024, George Sing, a Director at REGN sold 1,000.00 shares for a total of $992,500.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron (REGN) Company Description:

Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.